Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 909 of 6351
-
E-Learning could sharpen Doctors' eye for skin cancer
Knowledge-focused CompletedThe goal of this trial was to learn whether the MelaMEd online training program could improve doctors' skills in the early detection and management of melanoma, the most aggressive type of skin cancer. The participants were primary care physicians, including general practitioners…
Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Could a drug combo replace radiation for rectal cancer?
Disease control OngoingThis study is designed as a single-center, phase II exploratory clinical trial to evaluate the pathological response rate and safety of sintilimab (PD-1 inhibitor) combined with XELOX regimen (oxaliplatin + capecitabine) for neoadjuvant treatment of LARC. The study focuses on the…
Phase 2 • Sponsor: The First Affiliated Hospital of Anhui Medical University • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Milder chemo before transplant could help older blood cancer patients
Disease control Recruiting nowIn this multiple-center phase II study, the aim is to evaluate the clinical outcome of reduced intensity conditioning regimen with fludarabine (150mg/m2), busulfan (6.4mg/kg) and melphalan (100mg/m2) in patients with myeloid malignancies including AML, MDS and CMML \>=55 years.
Phase 2 • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug combo PrimeC shows promise in slowing ALS
Disease control Completed69 subjects with ALS will be enrolled in the study and randomized at a 2:1 ratio to receive the study drug or placebo tablets. Randomization sequences will be in random block sizes and stratified for ENCALS risk category \[high risk ≥ -4.5 vs. low risk \< -4.5\], and for backgrou…
Phase 2 • Sponsor: NeuroSense Therapeutics Ltd. • Aim: Disease control
Last updated Jun 26, 2026 14:14 UTC
-
Could a new injection replace bone cement for spine fractures?
Disease control OngoingThis is a multicenter, single-blinded, randomized controlled clinical trial evaluating the safety and efficacy of the AGN1 LOEP SV Kit for the treatment of painful vertebral compression fragility fractures (VCFs). The objective of this study is to demonstrate non-inferiority of t…
Sponsor: AgNovos Healthcare, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Brain zaps tailored to you: new hope for stubborn depression?
Disease control CompletedThis study will investigate the anti-anhedonic efficacy of a novel neurostimulation strategy termed accelerated intermittent theta burst stimulation (aiTBS) in participants with treatment resistant depression (TRD).
Sponsor: Stanford University • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New drug combo aims to boost Chemotherapy's punch against pancreatic cancer
Disease control OngoingThis is a multicentre, open label, two-part study to determine whether the focal adhesion kinase (FAK) inhibitor AMP945, when given prior to dosing with gemcitabine and nab-paclitaxel, improves response to therapy in first-line patients with unresectable or metastatic pancreatic …
Phase 1/2 • Sponsor: Amplia Therapeutics Limited • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Sniffing your way back: does scent therapy rebuild COVID-Shattered smell?
Disease control Recruiting nowOlfactory dysfunction is a defining symptom of COVID-19 infection. Studies have demonstrated improved olfaction in patients with post infectious olfactory dysfunction after an olfactory training (OT). The aim of this study is to assess the clinical outcomes of olfactory training …
Sponsor: Université du Québec à Trois-Rivières • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
A High-Tech knee brace could transform At-Home rehab for seniors
Symptom relief CompletedThis study evaluated a wearable electrogoniometry-based telerehabilitation system designed to support recovery after total knee arthroplasty. Participants followed a home-based rehabilitation program, while patients in the intervention group additionally used a wearable knee devi…
Sponsor: University of Chile • Aim: Symptom relief
Last updated Aug 23, 2026 00:00 UTC
-
Plant-Based diet shows promise for diabetes remission in new study
Disease control Stopped earlyThe incidence of type 2 diabetes worldwide is growing rapidly, being one of the fastest growing global health emergencies of the 21st century according to the International Diabetes Federation. In MicrobiAr the investigators seek to achieve type 2 diabetes remission through a pla…
Sponsor: National Council of Scientific and Technical Research, Argentina • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New hope for young adults with stubborn obesity: drug boosts weight loss
Disease control CompletedIntroduction: The increasing prevalence of obesity is particularly pronounced among adolescents. Currently available treatment options consist of structured lifestyle interventions. However, 25 % of adolescents do not respond to lifestyle treatment, why new effective treatment s…
Phase 4 • Sponsor: Signe Torekov • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New combo therapy shows promise for hard-to-treat lung cancer
Disease control OngoingThe goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy (SG), and its dosing in combination with pembrolizumab or pembrolizumab and a platinum agent (carboplatin or cisplatin), in participants with advanced or metastatic (cancer that has …
Phase 2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New pill offers hope for kids with severe colitis
Disease control Recruiting nowThe purpose of this study is to evaluate the effectiveness and safety of ozanimod (RPC1063) in achieving and maintaining clinical remission. Ozanimod will be administered orally to pediatric participants with moderate to severe active ulcerative colitis (UC) who have had an inade…
Phase 2/3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New hope for rare kidney disease: phase 3 trial of DMX-200 launches
Disease control Recruiting nowDMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor that, when administered concurrently with an ARB, is designed to inhibit recruitment of monocytes implicated in the inflammatory chemokine environment of chronic disease. The purpose of this pivotal rando…
Phase 3 • Sponsor: Dimerix Bioscience Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New drug may tame rare vasculitis and cut steroid dependence
Disease control OngoingThe purpose of this study is to compare mepolizumab-based regimen to conventional therapeutic strategy for remission induction in patients with Eosinophilic Granulomatosis with Polyangiitis.
Phase 3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New hope for lymphoma patients: Chemo-Free treatment shows promise
Disease control Recruiting nowThe purpose of this study is to find out if mosunetuzumab is an effective treatment in people with follicular lymphoma that was recently diagnosed and have not yet received any treatments for their disease.
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for lung cancer: targeted pill tested after other treatments fail
Disease control OngoingA Phase 2, Multi-Center, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Lorlatinib Monotherapy in Crizotinib and Platinum-based Chemotherapy Treated Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)Subjects in China
Phase 2 • Sponsor: CStone Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Period blood may hold key to endometriosis diagnosis
Diagnosis By invitation onlyThis product will be used as a diagnostic test to screen for the likelihood of endometriosis in menstruating adults with symptoms suggestive of endometriosis. The purpose of the test will be to guide clinical decisions regarding: 1) whether to undergo diagnostic laparoscopy to co…
Sponsor: Northwell Health • Aim: Diagnosis
Last updated Jun 27, 2026 13:02 UTC
-
New heart device aims to cut stroke risk without Long-Term blood thinners
Disease control PausedThe CLAAS® device will be evaluated for safety and efficacy by establishing its performance is non-inferior to the commercially available WATCHMAN® and Amulet™ left atrial appendage closure devices in patients with non-valvular atrial fibrillation. Patients who are eligible for t…
Sponsor: Conformal Medical, Inc • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New hope for shock patients: valve repair may save lives
Disease control Recruiting nowMitral regurgitation may be seen in the setting of cardiogenic shock. Transcatheter edge-to-edge repair (TEER) has been shown to improve outcomes in patients with chronic heart failure. Observational studies suggest improvements in clinical outcomes in patients with mitral regurg…
Sponsor: Ottawa Heart Institute Research Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC